The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)

Nikolas von Bubnoff, Sivahari Prasad Gorantla, Silvia Thöne, Christian Peschel, Justus Duyster

Open source

DOI
10.1182/blood-2006-01-0285
Published
2006-06-15
Container
Blood
Publisher
American Society of Hematology
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1182/blood-2006-01-0285,
  title = {The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)},
  author = {Nikolas von Bubnoff and Sivahari Prasad Gorantla and Silvia Thöne and Christian Peschel and Justus Duyster},
  year = {2006},
  journal = {Blood},
  doi = {10.1182/blood-2006-01-0285},
  url = {https://doi.org/10.1182/blood-2006-01-0285}
}

RIS

TY  - JOUR
TI  - The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)
AU  - Nikolas von Bubnoff
AU  - Sivahari Prasad Gorantla
AU  - Silvia Thöne
AU  - Christian Peschel
AU  - Justus Duyster
PY  - 2006
JO  - Blood
DO  - 10.1182/blood-2006-01-0285
UR  - https://doi.org/10.1182/blood-2006-01-0285
ER  - 

APA

Bubnoff, N. V., Gorantla, S. P., Thöne, S., Peschel, C., & Duyster, J. (2006). The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood. https://doi.org/10.1182/blood-2006-01-0285

Source records